10th World Congress and Expo on Cell & Stem Cell Research March 19-21, 2018 New York, USA

Haval Shirwan is Dr. Michael and Joan Hamilton Endowed Chair in Autoimmune Disease, Professor of Microbiology and Immunology, Director of Molecular Immunomodulation Program at the Institute for Cellular Therapeutics. He conducted his Graduate studies at the University of California in Santa Barbara, CA, and Postdoctoral studies at California Institute of Technology in Pasadena, CA. He joined the University of Louisville in 1998 after holding academic appointments at various academic institutions in the United States. He is member of several national and international societies and recipient of various awards.

Dr. Haval Shirwan research focuses on the modulation of immune system for the treatment of immune-based diseases with particular focus on type 1 diabetes, transplantation, and development of prophylactic and therapeutic vaccines against cancer and infectious diseases. He is an inventor on over a dozen of worldwide patents, widely published, organized and lectured at numerous national/international conferences, served on study sections for various federal and non-profit funding agencies, and is on the Editorial Board of a dozen of scientific journals.

Professor Mariusz Z. Ratajczak is a Head of Department of Regenerative Medicine at Warsaw Medical University, President of the Polish Society of Regenerative Medicine and Foreign Member of Polish Academy of Art and Sciences. He is also Professor of Medicine, the Henry and Stella Hoenig Endowed Chair in Cancer Biology and the Director of the Developmental Biology Research Program at the University of Louisville’s James Graham Brown Cancer Center. He is an internationally known specialist in the field of adult stem cell biology. His 2005 discovery of embryonic-like stem cells in adult bone marrow tissues has the potential to revolutionize the field of regenerative medicine.

Dr. Ratajczak is an internationally known specialist in the field of adult stem cell biology. His 2005 discovery of embryonic-like stem cells in adult bone marrow tissues has the potential to revolutionize the field of regenerative medicine. This discovery may lead to new treatments for cancer, heart disease, eye disease, diabetes and neurodegenerative disorders.

Dr. Andrew S. Chi, MD, PhD has been Chief of Neuro-Oncology and Co-Director of NYU Langone Brain Tumor Center at NYU Langone Medical Center LLC since October 2015. Dr. Chi served at Massachusetts General Hospital, Dana-Farber/Harvard Cancer Center and Harvard Medical School.

Andrew S. Chi's scientific interests include Brain Neoplasms, Glioma, Glioblastoma, Angiogenesis Inhibitors, Neoplasm Recurrence, Local

Davis is a graduate of Harvard Medical School and had his postgraduate medical training at Albert Einstein College of Medicine and the NIH. His academic positions have included Chair, Department of Medicine, Albany Medical College. He has served as President, American Thyroid Association, as a member of the Board of Directors of the American Board of Internal Medicine and he is Co-Head, Faculty of 1000 – Endocrinology. He serves on multiple Editorial Boards of His scientific interests include molecular mechanisms of actions of nonpeptide hormones, particularly, thyroid hormone. He and his colleagues described the cell surface receptor for thyroid hormone on integrin v3 that underlies the pro-angiogenic activity of the hormone and the proliferative action of the hormone on cancer cells. He has co-authored more than 200 original research articles and 30 textbook chapters and he has edited three medical textbooks.

Paul J. Davis's scientific interests include molecular mechanisms of actions of nonpeptide hormones, particularly, thyroid hormone. He and his colleagues described the cell surface receptor for thyroid hormone on integrin v3 that underlies the pro-angiogenic activity of the hormone and the proliferative action of the hormone on cancer cells

Professor Diana Anderson completed her PhD in the Faculty of Medicine, University of Manchester, UK. She currently holds the Established Chair in Biomedical Sciences at the University of Bradford. She has published over 450 papers and eight books. She has served on 10 editorial boards, has supervised 30 PhD students and is Editor- in- Chief of the Book Series “Issues in Toxicology” for the Royal Society of Chemistry. She has hosted and participated in 56 meetings for the WHO on Chemical Safety. She has been a Vice President of the Institute of Biology.

Her research interests mainly focuses on cancer, oxygen radicals, human biomonitoring, unbalanced precursor pools, dietary imbalance, male-mediated developmental defects, nanotoxicology, general toxicology

Esma S. Yolcu is Associate Professor of Microbiology and Immunology and the Director of Imaging Facility at the Institute for Cellular Therapeutics and member of James Brown Cancer Center, University of Louisville, Louisville, KY. Dr. Yolcu received her Ph.D. degree from University of Ankara, Ankara, Turkey and joined the University Of Louisville School Of Medicine in Louisville, KY, to pursue her postdoctoral training. Dr. Yolcus research focuses on novel immunomodulatory approaches for the induction of tolerance to auto and alloantigens for the purpose of treating rejection and autoimmunty. Dr. Yolcu is the recipient of several awards, member of various national and international societies, serves on Editorial Board of scientific journals, and published over 67 peer-reviewed papers, abstracts, and review articles in high ranking journals, such as Immunity, Circulation, Blood, and the Journal of Immunology.

Dr. Yolcu’s research interests include developing strategies to induce tolerance to auto and alloantigens for the purpose of treating autoimmune diseases and preventing allograft rejection. She co-pioneered a novel technology described as ProtEx™ with Dr. Shirwan as a practical alternative to gene therapy to display immunoregulatory molecules on the surface of bone marrow cells and use such engineered cells as a means of immunomodulation to establish mixed allogeneic hematopoietic chimerism under non-myeloablative conditions without graft-related toxicity such as graft versus host disease.